Coreline Soft, Co., Ltd.
Coreline Soft Co., Ltd. develops medical software to provide diagnosis and image solution for lung diseases. It offers AVIEW Metric-Lung, a quantitative image biomarker software of COPD using chest CT images; AVIEW Modeler, a three-dimensional (3D) modeling software for 3D printing; and AVIEW Research, a software for medical research data management. The company was founded in 2012 and is based i… Read more
Coreline Soft, Co., Ltd. (384470) - Net Assets
Latest net assets as of March 2025: ₩3.46 Billion KRW
Based on the latest financial reports, Coreline Soft, Co., Ltd. (384470) has net assets worth ₩3.46 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩24.86 Billion) and total liabilities (₩21.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩3.46 Billion |
| % of Total Assets | 13.91% |
| Annual Growth Rate | 29.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 253.55 |
Coreline Soft, Co., Ltd. - Net Assets Trend (2022–2024)
This chart illustrates how Coreline Soft, Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Coreline Soft, Co., Ltd. (2022–2024)
The table below shows the annual net assets of Coreline Soft, Co., Ltd. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩3.66 Billion | -68.71% |
| 2023-12-31 | ₩11.71 Billion | +438.40% |
| 2022-12-31 | ₩2.17 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coreline Soft, Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2843083951000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.42 Billion | 175.11% |
| Other Components | ₩56.87 Billion | 1552.22% |
| Total Equity | ₩3.66 Billion | 100.00% |
Coreline Soft, Co., Ltd. Competitors by Market Cap
The table below lists competitors of Coreline Soft, Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scottie Resources Corp
OTCQB:SCTSF
|
$33.31 Million |
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
$33.33 Million |
|
Sunty Development Co Ltd
TW:3266
|
$33.34 Million |
|
African Rainbow Capital Investments Ltd
JSE:AIL
|
$33.34 Million |
|
IMMUCELL CORP. DL-10
F:IUL
|
$33.28 Million |
|
Shine-On BioMedical Co.,Ltd.
TWO:6926
|
$33.28 Million |
|
Hsin Ba Ba Corp
TW:9906
|
$33.28 Million |
|
Gala Precision Engineering
NSE:GALAPREC
|
$33.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coreline Soft, Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,709,660,740 to 3,664,069,400, a change of -8,045,591,340 (-68.7%).
- Net loss of 14,137,902,350 reduced equity.
- Share repurchases of 772,759,010 reduced equity.
- Other factors increased equity by 6,865,070,020.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-14.14 Billion | -385.85% |
| Share Repurchases | ₩772.76 Million | -21.09% |
| Other Changes | ₩6.87 Billion | +187.36% |
| Total Change | ₩- | -68.71% |
Book Value vs Market Value Analysis
This analysis compares Coreline Soft, Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.26x to 12.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩167.86 | ₩3400.00 | x |
| 2023-12-31 | ₩875.76 | ₩3400.00 | x |
| 2024-12-31 | ₩264.25 | ₩3400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coreline Soft, Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -385.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -359.82%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 6.73x
- Recent ROE (-385.85%) is below the historical average (-325.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -469.56% | -249.63% | 0.73x | 2.57x | ₩-10.43 Billion |
| 2023 | -120.27% | -343.43% | 0.26x | 1.35x | ₩-15.25 Billion |
| 2024 | -385.85% | -359.82% | 0.16x | 6.73x | ₩-14.50 Billion |
Industry Comparison
This section compares Coreline Soft, Co., Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $80,735,275,073
- Average return on equity (ROE) among peers: -13.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coreline Soft, Co., Ltd. (384470) | ₩3.46 Billion | -469.56% | 6.19x | $33.29 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |